Published: Oct 30, 2021
WASHINGTON - Regulators on Friday authorized the Pfizer-BioNTech coronavirus vaccine for children 5 to 11 years old, a watershed moment celebrated by parents yearning for a return to normal life but viewed with ambivalence and outright skepticism by others worried about the potential risk of unknown side effects.
Published: Oct 27, 2021
The FDA will consider formal authorization of the Pfizer-BioNTech COVID-19 vaccine based on its advisors recommendation. If authorized, it would be the first COVID-19 vaccine for younger children.
Published: Oct 21, 2021
WASHINGTON - Millions more people in the United States will soon be able to receive an extra dose of any coronavirus vaccine, regardless of their initial vaccination - a flexibility that comes along with the authorization Wednesday of the Moderna and Johnson & Johnson booster shots by federal regulators.
Published: Oct 16, 2021
A U.S. FDA advisory committee voted unanimously to recommend authorization of a second dose of Johnson & Johnsons COVID-19 vaccine as early as two months after the primary shot for anyone aged 18 and older.
Published: Oct 08, 2021
U.S. pharmaceutical firm Pfizer and its German partner, BioNTech, have asked the Food and Drug Administration to authorize their coronavirus vaccine for emergency use for children 5 to 11 years old, the companies announced Thursday.